As Verge Genomics plugs away at its amyotrophic lateral sclerosis (ALS) program, it is teaming up with Eli Lilly to pursue even more targets for new treatments against the devastating disease.
The neuroscience-focused drug discoverer will pick up $25 million in an upfront fee, equity and near-term payments but stands to collect up to $694 million down the line. Under the three-year deal, Verge will use its artificial-intelligence-powered drug discovery platform to identify new targets of which Lilly may select up to four to push into clinical development and commercialization.
“How should I live my life?" Sadly, I don't have an answer to this question, only you can answer this question for your life, but I do have five points which may help you.
There is an urgent need for new and improved therapies for ALS, as there is still no cure. The Clinical Trials Awards Program is open to industry and academic investigators proposing to develop novel or repositioning approaches for ALS.
Thanks to the tireless efforts of ALS advocates across the country, the House included many of our aggressive requests for new and increased investments in research to find treatments and a cure, slow symptom progression, reduce the number of new cases, and increase the length and quality of life for every American living with ALS.
The ALS Association and the U.S. Department of Veterans Affairs (VA) have entered into a partnership to help improve the lives of Veterans living with ALS by increasing the number of Veterans Health Administration (VHA) clinics that are designated as Certified Treatment Centers of Excellence and Recognized Treatment Centers.
Across the country, teams of health care professionals specially trained to address the needs of people living with ALS are doing whatever it takes to provide the specialized care and support their patients require.
In very powerful testimony, members of the ALS community asked members of Congress to ensure the FDA acts with greater speed and regulatory flexibility during a hearing before the House Energy and Commerce Health Subcommittee.
As part of this year’s National Advocacy Conference, Dr. Bryan Traynor, senior investigator and chief of neuromuscular diseases at the NIH’s National Institute on Aging presented a case study to the ALS community to help better understand what we know today and what we are working toward for the future relating to genetics and prevention. ALS prevention has not only been a priority for Traynor, but for the ALS community at large.